Trials / Completed

CompletedNCT00193193

Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma

A Randomized, Phase II Trial of Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin Administered Either Weekly or Every Four Weeks in the Treatment of Hormone Refractory Prostate Carcinoma

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 100 (planned)

Sponsor: SCRI Development Innovations, LLC · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

In this trial we will investigate how this three-drug regimen may be improved, both with respect to efficacy and toxicity, by making some modifications in the dosing and schedule in the treatment of patients with hormone refractory prostate cancer.

Detailed description

Upon determination of eligibility, patients will receive: Paclitaxel + Estramustine + Carboplatin Patients will receive weekly paclitaxel and low-dose estramustine, in combination with carboplatin administered either weekly r every four weeks.

Conditions

Prostate Cancer

Interventions

Type	Name	Description
DRUG	Paclitaxel
DRUG	Estramustine
DRUG	Carboplatin

Timeline

Start date: 2000-08-01
Primary completion: 2003-12-01
Completion: 2007-02-01
First posted: 2005-09-19
Last updated: 2010-08-04

Source: ClinicalTrials.gov record NCT00193193. Inclusion in this directory is not an endorsement.